177Lu-LNC1009 / Lannacheng Biotechnology - LARVOL DELTA

Safety, Biodistribution, and Dosimetry of FAP and Integrin αvβ3 Dual-Targeting Radioligand 177Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas. (PubMed, J Nucl Med) - " This first-in-human, dual-targeting radiopharmaceutical therapy agent 177Lu-LNC1009 demonstrated favorable dosimetry, high tumor radiation delivery, and encouraging preliminary efficacy across a variety of advanced solid tumors. Future ligand structural optimization and refined screening protocols are warranted to improve safety and further efficacy in multicycle, tumor-specific dose-escalation trials."

First-in-human • Journal • P1 data • Preclinical • Hematological Disorders • Kidney Cancer • Leukopenia • Oncology • Renal Cell Carcinoma • Solid Tumor • Thrombocytopenia